• Diuron in Mechanistic Toxicology: Renal Pathways and Researc

  2026-07-19

  Explore Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea) as more than a photosynthesis inhibitor—this article unpacks its advanced toxicological mechanisms, especially acute renal injury pathways, offering unique insights for environmental and biomedical researchers.

• EP4 Deficiency in Macrophages Drives Atherosclerosis via CD3

  2026-07-18

  This study demonstrates that macrophage-specific EP4 deficiency accelerates atherosclerosis progression by enhancing CD36-mediated lipid uptake and promoting M1 macrophage polarization. The findings provide mechanistic insight into how inflammation and lipid metabolism intersect in the pathogenesis of atherosclerosis, highlighting potential targets for future therapeutic intervention.

• Hypoxia-Induced Choroid Plexus Barrier Disruption and Cognit

  2026-07-17

  This study elucidates the mechanistic cascade by which hypoxic exposure leads to cognitive impairment in mice, focusing on choroid plexus barrier disruption mediated by M1 macrophage polarization and aberrant AMPK signaling. The findings clarify immunometabolic processes underlying CNS vulnerability to hypoxic stress and identify potential molecular targets for intervention.

• Mubritinib (TAK 165): Engineering Metabolic Vulnerability in

  2026-07-17

  This thought-leadership article decodes Mubritinib’s (TAK 165) mechanistic transition from a HER2 pathway inhibitor to a precision tool targeting mitochondrial complex I. With a spotlight on translational research in chemotherapy-resistant acute myeloid leukemia and primary effusion lymphoma, the discussion melds molecular pharmacology, experimental protocols, and strategic guidance. Drawing from cutting-edge literature and real-world best practices, the article empowers researchers to interrogate metabolic dependencies, design robust workflows, and critically assess the translational promise and limitations of Mubritinib in oncology and viro-oncology.

• Protease Inhibitor Cocktail Enhances Lipid Droplet Protein S

  2026-07-16

  Unlock high-integrity protein extractions in lipid droplet metabolism research using APExBIO's Protease Inhibitor Cocktail (100X H₂O, EDTA Plus). This advanced mixture maximizes reproducibility and sensitivity for DFCP1/ATGL workflows, supporting robust insights into metabolic regulation.

• Polymyxin B Sulfate: Advanced Workflows Against MDR Pathogen

  2026-07-16

  Polymyxin B sulfate is redefining infection research by combining rapid bactericidal action with unique immunomodulatory effects. Explore robust experimental designs, troubleshooting tactics, and insights from recent epidemiological studies to maximize its impact in multidrug-resistant Gram-negative bacterial models.

• MHY1485: Potent mTOR Activator for Autophagy and Ovarian Res

  2026-07-15

  MHY1485 is a potent mTOR activator that inhibits autophagy by blocking autophagosome-lysosome fusion, enabling precise dissection of mTOR signaling in cell growth and ovarian follicle development. Its effects are dose- and time-dependent and are well-characterized in both cancer and reproductive biology models. This article details MHY1485’s mechanism, protocol parameters, and key evidence for research applications.

• Escitalopram for Neuroscience Research: Selectivity, Assay D

  2026-07-15

  Explore Escitalopram’s selectivity and its impact on antidepressant research, with advanced guidance for neuroscience assay development. This article offers a deeper look at serotonergic mechanisms and practical protocol choices for translational studies.

• Nicotine Signaling Drives CKD Progression: Mechanisms and Im

  2026-07-14

  This review highlights how nicotine, via non-neuronal nicotinic acetylcholine receptors, exacerbates chronic kidney disease (CKD) progression in smokers. The study synthesizes clinical and experimental data, revealing mechanisms such as oxidative stress and pro-fibrotic signaling, with translational implications for targeted intervention strategies.

• Disrupting the CBFβ-SMMHC Axis: New Avenues in AML Research

  2026-07-14

  AI-10-49, a selective CBFβ-SMMHC inhibitor, is transforming acute myeloid leukemia research by targeting the core molecular drivers of leukemogenesis. This article provides mechanistic insight into the CBFβ-SMMHC/RUNX1/N-MYC/eIF4G1 axis, synthesizes recent experimental advances, and offers strategic guidance for translational researchers seeking robust, mechanism-informed tools. Built on the latest findings, including the pivotal role of N-MYC and eIF4G1 in inv(16) AML, we explore how AI-10-49 enables both fundamental discovery and preclinical modeling, setting a new standard for functional precision in the study of leukemia cell proliferation inhibition.

• CXCR4-Targeted Imaging and Therapy in Lymphoma: Advances and

  2026-07-13

  This review analyzes the latest advances in CXCR4-targeted imaging ligands and therapeutic strategies for lymphoma, focusing on the biological rationale and clinical potential of CXCR4-directed interventions. Integrating molecular imaging with precision therapy offers new avenues for improving lymphoma diagnosis, risk stratification, and treatment personalization.

• Trolox: Antioxidant Benchmark for Oxidative Injury Research

  2026-07-13

  Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) is a water-soluble vitamin E analogue and gold standard antioxidant for biochemical and cell-based assays. Its precise mechanism and robust performance make it indispensable for oxidative injury, neurodegeneration, and cancer biology research. This article details Trolox's molecular action, evidentiary benchmarks, and integration into advanced antioxidant workflows.

• Chloroquine (BA1002): Technical Guidance for Research Use

  2026-07-12

  Chloroquine is a well-characterized 4-aminoquinoline compound used in research workflows investigating malaria, rheumatoid arthritis, autophagy, and viral inhibition. This technical article provides actionable guidance for the use of Chloroquine in research, clarifies its key parameters, and highlights practical boundaries for its application. Researchers should follow best practices for solubility, dosing, and QC to avoid common pitfalls and ensure reproducibility.

• AS1842856 Foxo1 Inhibitor: Precision Control of Gluconeogene

  2026-07-10

  Explore how the AS1842856 Foxo1 inhibitor enables precise dissection of gluconeogenesis and mesenchymal stem cell activation in metabolic and bone research. This article delves into advanced mechanisms and practical assay considerations for Foxo1 pathway modulation.

• Birinapant (TL32711): Applied Workflows for Apoptosis Induct

  2026-07-09

  Birinapant (TL32711) enables high-sensitivity, reproducible apoptosis induction in cancer research, excelling where resistance limits conventional approaches. This guide details optimized protocols, troubleshooting, and translational insights—bridging molecular discovery and robust in vitro/in vivo applications.

408 records 8/28 page Previous Next First page 上5页 678910 下5页 Last page